1-deoxymannojirimycin (DMJ), targeting mannosidase I |
1 mM |
A/chick/Germany/49 (H10N7) |
MDCK |
HA expression unaffected |
Burke et al. (1984) |
|
|
|
Infectivity (slight). No effect on production |
|
2, 10, 25 μg/ml |
A/NWS/33 (H1N1) |
MDCK |
High-mannose oligosaccharide processing and complex chain formation |
Elbein et al. (1984a) |
|
|
|
No effect on hemagglutination |
|
25 μg/ml plus 100 μg/ml CAST |
A/NWS/33 (H1N1) |
MDCK |
No inhibition of oligosaccharide processing (CAST concentration too low to inhibit α-glucosidases) |
|
|
|
|
Not tested |
|
0.25, 0.5, 1, 2, 4 mM |
A/Puerto Rico/8/34 (H1N1) |
MDCK |
Mannose incorporation (50% at >2 mM) |
|
|
|
|
Not tested |
|
0.05, 0.1, 0.25, 0.5, 1, 2, 4 mM |
A/Puerto Rico/8/34 (H1N1) |
CEC |
Mannose incorporation |
|
|
|
|
Not tested |
|
1, 10, 50 μg/ml |
Unknown |
MDCK |
Unaffected |
Elbein et al. (1990) |
|
|
|
Not tested |
|
1,4-dideoxy-1,4-imino-d-mannitol (DIM), targeting mannosidase I and II |
10, 100, 250 μg/ml |
A/NWS/33 (H1N1) |
MDCK |
High-mannose oligosaccharide processing |
Palamarczyk et al. (1985) |
|
|
|
Not tested |
|
Kifunensine, targeting mannosidase I |
10, 100 ng/ml 1, 10 μg/ml |
Unknown |
MDCK |
High-mannose oligosaccharide processing and complex chain formation |
Elbein et al. (1990) |
|
|
|
Not tested |
|
0.18 mM |
A/Puerto Rico/8/34/MS (H1N1) |
MDCK |
HA sulfation |
Karaivanova & Spiro (1998) |
|
|
|
Not tested |
|
0.18 mM |
A/Puerto Rico/8/34/MS (H1N1) |
LLC-PK1
|
HA sulfation |
|
|
|
|
Not tested |
|
N-benzyl-1,5-dideoxy-1,5-imino-d-mannitol, targeting mannosidases |
10 mM |
A/fowl plague virus/Rostock/34 (H7N1) |
MDCK |
Not tested |
Huang et al. (1991) |
|
|
|
Haemagglutination and CPE |
|
N-benzyl-1,5-dideoxy-1,5-imino-4,6-O-isopropylidene-d-mannitol, targeting mannosidases |
10 mM |
A/fowl plague virus/Rostock/34 (H7N1) |
MDCK |
Not tested |
Huang et al. (1991) |
|
|
|
Haemagglutination and CPE |
|
3-episiastatin B, targeting NA |
10, 20, 40, 100 μM |
A/Fort Monmouth/1/47 (H1N1) |
MDCK |
IC50 = 74 μM for NA |
Nishimura et al. (1993) |
|
|
|
PFU 11.1% of control at 40 μM |
|
100 μM |
A/Kayano/57 (H2N2) |
MDCK |
IC50 > 10 μM for NA |
|
|
|
|
Not tested |
|
100 μM |
B/Lee/40 |
MDCK |
IC50 = 42 μM for NA |
|
|
|
|
Not tested |
|
N-nonyl-deoxygalactonojirimycin (NN-DGJ), targeting ceramide-specific glucosyltransferase |
Titration |
A/Udorn/307/72 (H3N2) |
MDCK |
Not tested |
Hussain et al. (2015) |
|
|
|
HA titer 117 ± 19%, viral titer 97 ± 20%, plaque number 74 ± 16% and plaque size 88 ± 20% of control at 62.5 μM |
|
Titration |
A/Brisbane/10/2007 (H3N2) |
MDCK |
Not tested |
|
|
|
|
HA titer 75 ± 15%, viral titer 71 ± 21%, plaque number 60 ± 10% and plaque size 76 ± 4% of control at 62.5 μM |
|
Titration |
A/Lviv/N6/2009 (H1N1) |
MDCK |
Not tested |
|
|
|
|
HA titer 60 ± 10%, viral titer 85 ± 16% and plaque number 73 ± 8% of control at 62.5 μM. No effect on plaque size |
|